Carter B L, Woodhead J C, Cole K J, Milavetz G
College of Pharmacy, University of Iowa, Iowa City 52242.
Drug Intell Clin Pharm. 1987 Sep;21(9):734-8. doi: 10.1177/106002808702100914.
This study was designed to determine the incidence and severity of gastrointestinal (GI) side effects in patients taking erythromycin. More patients complained of GI side effects with the enteric-coated tablet (70.8 percent) than with the stearate (51.4 percent) or the ethylsuccinate (48.9 percent) salts. The enteric-coated tablet was associated with a higher incidence of individual adverse reactions; more patients discontinued it because of adverse GI effects. These data demonstrate a high incidence of GI side effects to erythromycin. Additionally, GI side-effect incidence appears to be higher with the enteric-coated tablet.
本研究旨在确定服用红霉素的患者胃肠道（GI）副作用的发生率和严重程度。与服用硬脂酸盐（51.4%）或琥乙红霉素（48.9%）盐的患者相比，更多服用肠溶衣片的患者抱怨有胃肠道副作用（70.8%）。肠溶衣片与更高的个体不良反应发生率相关；更多患者因胃肠道不良反应而停用该药。这些数据表明红霉素胃肠道副作用的发生率很高。此外，肠溶衣片的胃肠道副作用发生率似乎更高。
